Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05397665 · ClinicalTrials.gov registry record · Phase 2
Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency
A Phase 2 study of Hereditary Neuropathy Caused by SORD Deficiency, sponsored by Applied Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 10
- Study locations
NCT05397665 is a Phase 2 study of Hereditary Neuropathy Caused by SORD Deficiency that is active but no longer recruiting, run by Applied Therapeutics. The registered enrollment target is 56 participants. The trial reports 10 study locations across 10 states.
The verdict
NCT05397665, a Phase 2 study of Hereditary Neuropathy Caused by SORD Deficiency, is active but no longer recruiting, sponsored by Applied Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is designed to assess the efficacy and safety of AT-007 treatment in patients with SORD Deficiency. This randomized, double-blind study will assess the effect of AT-007 compared to Placebo in SORD Deficiency in patients for up to 24 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AT-007
Study Locations (10)
Colorado
- University of Colorado - Aurora
Florida
- University of Miami - Coral Gables
Iowa
- University of Iowa - Iowa City
Massachusetts
- Massachusetts General Hospital - Boston
New Jersey
- Hassman Research Institute - Berlin
New York
- University of Rochester - Rochester
Pennsylvania
- University of Pennsylvania - Philadelphia
Prague
- Axon Clinical, s.r.o. - Prague
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05397665
The ClinicalTrials.gov registry entry for NCT05397665 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Applied Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Neuropathy Caused by SORD Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05397665 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Colorado, Florida, Iowa.
Frequently Asked Questions
What is clinical trial NCT05397665 about?
NCT05397665 is a clinical study titled "Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency". This study is designed to assess the efficacy and safety of AT-007 treatment in patients with SORD Deficiency. This randomized, double-blind study will assess the effect of AT-007 compared to Placebo in SORD Deficiency in patients for up to 24 months.
What is the current status of trial NCT05397665?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2022-01-01. Estimated completion is 2026-10.
What conditions does trial NCT05397665 study?
This clinical trial studies the following conditions: Hereditary Neuropathy Caused by SORD Deficiency.
What interventions are being tested in trial NCT05397665?
The interventions under investigation include: Placebo (DRUG), AT-007 (DRUG).
Who is sponsoring clinical trial NCT05397665?
This trial is sponsored by Applied Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05397665 being conducted?
This trial has 10 study locations across Colorado, Florida, Iowa, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.